Literature DB >> 15295692

Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.

Ronald Swanstrom1, Ronald J Bosch, David Katzenstein, Hailong Cheng, Hongyu Jiang, Nicholas Hellmann, Richard Haubrich, Susan A Fiscus, Courtney V Fletcher, Edward P Acosta, Roy M Gulick.   

Abstract

We analyzed retrospectively, by use of logistic regression, the role of the phenotypic susceptibility score (PSS) as a determinant of virologic outcome in a study of treatment-experienced human immunodeficiency virus (HIV) type 1-infected subjects. A model for PSS in which each drug was treated equally and scored as active or inactive was not predictive of HIV-1 RNA load (VL) suppression. However, weighting the potential contribution of each drug on the basis of inferred potency and by use of a continuous scale to quantify drug susceptibility revealed significant associations between PSS and outcome. Entry VL was a strong independent predictor of therapy outcome, and PSS was a strong predictor of the magnitude of the initial decrease in VL. This suggests that the prospective evaluation of PSS to identify regimens that maximize decreases in VL to reduce the probability of virologic rebound could improve antiretroviral treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15295692     DOI: 10.1086/422692

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.

Authors:  Timothy J Wilkin; Zhaohui Su; Amy Krambrink; Jianmin Long; Wayne Greaves; Robert Gross; Michael D Hughes; Charles Flexner; Paul R Skolnik; Eoin Coakley; Catherine Godfrey; Martin Hirsch; Daniel R Kuritzkes; Roy M Gulick
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

2.  Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.

Authors:  Athe M N Tsibris; Zixin Hu; Roger Paredes; Kay E Leopold; Opass Putcharoen; Allison L Schure; Natalie Mazur; Eoin Coakley; Zhaohui Su; Roy M Gulick; Daniel R Kuritzkes
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

3.  Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity.

Authors:  Karen T Tashima; Katie R Mollan; Lumine Na; Rajesh T Gandhi; Karin L Klingman; Carl J Fichtenbaum; Adriana Andrade; Victoria A Johnson; Joseph J Eron; Laura Smeaton; Richard H Haubrich
Journal:  HIV Clin Trials       Date:  2015-07-27

4.  Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.

Authors:  Zhaohui Su; Roy M Gulick; Amy Krambrink; Eoin Coakley; Michael D Hughes; Dong Han; Charles Flexner; Timothy J Wilkin; Paul R Skolnik; Wayne L Greaves; Daniel R Kuritzkes; Jacqueline D Reeves
Journal:  J Infect Dis       Date:  2009-12-01       Impact factor: 5.226

5.  Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.

Authors:  Jeffrey A Anderson; Hongyu Jiang; Xiao Ding; Leslie Petch; Terri Journigan; Susan A Fiscus; Richard Haubrich; David Katzenstein; Ronald Swanstrom; Roy M Gulick
Journal:  AIDS Res Hum Retroviruses       Date:  2008-05       Impact factor: 2.205

6.  A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.

Authors:  Lisa M Demeter; Hongyu Jiang; A Lisa Mukherjee; Gene D Morse; Robin DiFrancesco; Robert DiCenzo; Carrie Dykes; Prakash Sista; Lee Bacheler; Karin Klingman; Alex Rinehart; Mary Albrecht
Journal:  AIDS       Date:  2009-01-28       Impact factor: 4.177

Review 7.  Clinical management of HIV drug resistance.

Authors:  Karoll J Cortez; Frank Maldarelli
Journal:  Viruses       Date:  2011-04-14       Impact factor: 5.048

8.  The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients.

Authors:  Niko Beerenwinkel; Hesam Montazeri; Heike Schuhmacher; Patrick Knupfer; Viktor von Wyl; Hansjakob Furrer; Manuel Battegay; Bernard Hirschel; Matthias Cavassini; Pietro Vernazza; Enos Bernasconi; Sabine Yerly; Jürg Böni; Thomas Klimkait; Cristina Cellerai; Huldrych F Günthard
Journal:  PLoS Comput Biol       Date:  2013-08-29       Impact factor: 4.475

9.  Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials.

Authors:  Becky Jubb; Marilyn Lewis; Lynn McFadyen; Paul Simpson; Julie Mori; Phylinda Chan; Barry Weatherley; Elna van der Ryst; Mike Westby; Charles Craig
Journal:  Antivir Chem Chemother       Date:  2019 Jan-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.